Recently, the azithromycin dry suspension developed by Shijiazhuang No.4 Pharmaceutical Co., Ltd. obtained the drug registration certificate issued by the State Drug Administration, and was deemed to have passed the consistency evaluation. It was the first domestic pharmaceutical enterprise to be approved.

It is reported that azithromycin dry suspension is the second generation macrolide antibiotic, which is mainly used to treat lower respiratory tract infections such as bronchitis and pneumonia caused by sensitive bacteria, skin and soft tissue infections, acute otitis media and upper respiratory tract infections such as nasosinusitis, pharyngitis and tonsillitis.

The approval of azithromycin dry suspension will help the diversified development of enterprise dosage forms, optimize the adjustment of product structure, accelerate the supply side structural transformation, and further promote the high-quality development of the enterprise. Up to now, there are 27 varieties and 36 products of Shijiazhuang No.4 Pharmaceutical Group that have passed or are deemed to have passed the national generic drug quality and efficacy consistency evaluation.